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tablet regimen and avoidance of an increased heart attack risk. Not being tied to 
mealtime dosing was a lower priority.
INFECTION – Health Care Use & Policy Studies
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Objectives: Antibiotics have played a magic role in controlling infectious diseases 
in humans. However their indiscriminate use and prescriptions have rendered over-
whelming level of pathogenic bacteria resistant, which has resulted in increased 
mortality, morbidity and increased rates of hospitalizations incurring significant 
economic losses. Self-medication and misprescription of antibiotics at pharmacy 
stores are one of the major contributory factors in speeding up this phenomenon of 
resistance in bacterial communities. The aim of this study was to survey and assess 
the unregulated and indiscriminate sale of antibiotics in pharmacy stores in Khyber-
Pakhtunkhwa province in Pakistan. MethOds: In this study several pharmacy stores 
in two major cities, Mardan and Swabi, in Khyber-Pakhtunkhwa province in Pakistan 
were checked on two criteria; whether there were qualified and certified pharmacists 
available, and whether they demanded any doctor/ hospital prescription while giv-
ing antibiotics. Results: About 80 percent of the people sitting on the counter in 
pharmacies were not certified pharmacists, and 100 percent did not bother to demand 
any doctor’s prescription while selling antibiotics. cOnclusiOns: This is an indica-
tion of an inevitable disaster to the healthcare system, which can potentially lead 
to enormous losses to human lives and economy. An urgent need of legislation on 
antibiotics therapy in Pakistan is the need of the day; otherwise we will be left with 
no choice than to surrender to deadly microbial diseases.
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Objectives: A high level of vaccine acceptance is an important requirement for suc-
cessful vaccination programmes. Therefore, vaccine acceptance is a common criteria 
considered in national immunisation decision-making processes. This systematic 
review aimed to assess the acceptance of herpes zoster (HZ) vaccination among 
the target group (i.e. people aged 50 years and older) and physicians. MethOds: A 
PubMed search was performed for identifying English and German language publica-
tions on studies assessing HZ vaccine acceptance published before June 2015. A study 
was included if it provided information on awareness, knowledge, attitudes and/or 
perceived barriers regarding HZ vaccination among people aged 50 years and older 
or physicians. Results: After the study selection process, 15 studies remained to be 
included in the review. Ten of these studies investigated aspects of vaccine acceptance 
in the target group. Five studies concentrated on the perspective of physicians. Almost 
all studies used quantitative research methods; one study used a qualitative design 
based on focus group interviews. Most of the interviewed patients and physicians 
attached great importance to the HZ vaccine. However, when compared to influenza 
and pneumococcal vaccination, HZ vaccination was considered as a less important 
clinical priority by physicians. From the perspective of the target group, the primary 
care physician’s recommendation was a crucial factor in reaching a high level of vac-
cine acceptance. The main barriers of vaccine acceptance were the price of the vac-
cine, concerns about side effects and the perception of low risk of HZ. cOnclusiOns: 
This review identified several factors influencing the acceptance of HZ vaccination. 
Successful implementation of HZ vaccination might depend on the health care pro-
vider’s attitude, the reimbursement of costs and the target group’s knowledge on HZ.
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Objectives: To describe patterns and factors influencing real-world management 
of Danish patients infected with Hepatitis C virus (HCV). MethOds: From DANHEP, 
a national Danish HCV/HBV registry, we identified HCV genotype 1 or 4 patients 
initiating the following treatment strategies between 2011 and 2014 (excluding 
early access programs): 2nd and 1st generation direct-acting antivirals (2GDAA 
and 1GDAA), dual therapy (DT), or no treatment (NT). Patients could have ≥ 1 treat-
ment episode. We estimated proportion treated, treatment duration, and describe 
patients according to HCV strategy initiated. Results: Among 1,988 patients with 
7,209 treatment episodes (including NT), proportion of patients treated yearly was 
low (range: 0.9-4.2%) and lowest in 2013, just prior to 2GDAA market entry. In 2014, 
96.4% (53/55) of treatment episodes (excluding NT) were with 2GDAAs. Most 2GDAA 
treatments initiated were interferon-free (N= 44/53; 83.0%), with uptake highest 
for simeprevir-sofosbuvir (31/53; 58.5%) and sofosbuvir-daclatasvir (11/53; 20.8%) 
combination therapy. Average completed treatment duration (in weeks) with 
2GDAAs (13.8, SD= 5.4; N= 33) was shorter than for 1GDAAs (32.0, SD= 17.7; N= 102) 
and DT (32.2, SD= 17.9; N= 42), in accordance with approved treatment duration. 
Interferon-free 2GDAA treatment with ribavirin (16.6, SD= 4.7; N= 12) was longer 
than without ribavirin (12.0, SD= 4.4; N= 13); ribavirin may selectively be used for 
harder to treat patients as suggested by higher cirrhosis prevalence (76.9% vs. 56.5%) 
and previous treatment exposure (64.7% vs. 44.4%). Patients initiating 2GDAAs 
were more commonly cirrhotic (55.6% vs. 30.8% for 1GDAA, 35.3% for DT, 15.5% for 
NT) and previously treated (50.9% vs. 35.3% for 1GDAA, 26.2% for DT, 3.7% for NT) 
than initiators of other strategies, in line with Danish reimbursement criteria for 
2GDAAs. cOnclusiOns: Proportion of patients treated remains low (< 5%), despite 
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Objectives: Existing tools for sexual function are mostly focused to the erectile 
dysfunction and do not measure the domains important for patients living with 
HIV/AIDS (PLVHA) or HCV (PLVHC) such as stigma, fear of transmission, or type 
of sexual practices. MethOds: An exploratory descriptive qualitative phenom-
enological study was conducted in France based on face to face interviews with 
PLVHA and/or PLVHC. Sample was selected to represent different medical, social 
and demographic situations. The open coding of the interviews allowed validat-
ing a book of 433 codes. They were organized into dimensions of the conceptual 
framework. Results: 28 interviews were conducted: 17 PLVHA, 8 PLVHC and 3 
co-infected. The median age was 48.5 years [29; 74] with 11 women, 6 men and 
1 transsexual. The transmission modes were homosexual (11), heterosexual (10), 
intravenous drug use (5) and blood transfusion (2). Majority of PLVHA (88.2 %) 
and all co-infected were under HIV treatment. The thematic coding revealed the 
following dimensions: HIV impact, sexuality (sexual life, practice, satisfaction 
and difficulties), prevention and HIV comprehensive care, partners, social life, 
psychological impact, internet use and perception discrepancies. Most of these 
concepts are new or bring more detail than the tools in current use. Men having 
sex with men population described specific topics such as stigma and substance 
use. Sexuality difficulties were diverse: problems of libido or erection, sexual 
performance and pleasure, reluctance to have sex, sexual intercourse in spite of 
oneself, fear of transmission or of contamination and difficulty of using condoms. 
The deterioration in the quality of sexual life was reflected in global sexual dis-
satisfaction. cOnclusiOns: Sexual dysfunction in PLVHA and PLVHC is important 
and frequent. Qualitative analysis and description of the concepts have led to the 
creation of the framework of a future specific questionnaire.
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Objectives: To understand the relationship between socio-demographic variables, 
clinical factors, highly active anti-retroviral therapy (HAART) and health related 
quality of life (QoL) in HIV-infected individuals participants in the IANUA mul-
ticenter study. MethOds: Data relating to patients with HIV infection admitted 
to 3 infectious disease units in Genoa (Italy) between 2012 and 2014 are collected 
and analyzed. Univariate and multivariate association of demographic and clinical 
factors with QoL (computed using EQ-5D-3L) are examined. QoL determinants are 
assessed using a tobit model, while a logistic model is implemented in order to 
investigate the relation between specific patients characteristics and the likelihood 
of having higher QoL. Results: Results of the empirical modeling suggest that 
being Italian and having a job are positively associated with QoL, whereas being a 
female, taking other drugs in addition to anti-retroviral drugs and being subsidis-
ied are negatively related to QoL. Among clinical factors, last CD4 cell count level 
cannot be considered as significant predictor of QoL, while higher QoL seem to be 
defined by single tablet regimens. cOnclusiOns: The study investigates the major 
determinants of QoL among HIV patients and the results provide some informative 
tools useful to improve strategies aiming at maximizing QoL. As monitoring of QoL is 
nowadays a priority for clinicians, further work will be based on “dynamic” analysis 
comparing QoL at the initial time and QoL at 6-months follow up.
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Objectives: The objective was to estimate patient preferences for simplified treat-
ment regimens, amongst UK HIV patients currently treated with anti-retroviral 
therapy (ART). MethOds: Data were collected via a prospective web-based survey 
(June to October 2014) comprising a discrete choice experiment. A d-efficient design 
was developed in Ngene comprising 12 hypothetical choices of two drug scenarios 
with five attributes (number of tablets (1 to 4), mealtime dosing, increased risk of 
heart attack or insomnia (yes/no), and monthly cost to the healthcare system (£500, 
£600, £750, £1000)). A steering committee of clinicians, nurses, pharmacists, patient 
group representatives and academics, guided the survey design which was tested by 
UK patients. The response patterns were analysed in STATA v13 using generalised 
multinomial logit models (GMNL), including scale heterogeneity multinomial logit, 
mixed logit and fixed-effect logit models. Willingness to pay (WTP) in GBP was used 
as a metric to quantify the strength of preference for each attribute. Results: 
Results: Responses were analysed for 278 UK patients currently receiving ART. 72.6% 
were men who have sex with men, 14.7% were female. Median age was 44 (range 
21-66) years, time since diagnosis 8 (0-30) years and 5 (0-27) years duration of treat-
ment. Across the models, the attributes were ranked similarly, though the range 
of WTP was more extreme for some models than others. Based on the best fitting 
model (GMNL with correlated random-effects), patients were most willing to pay 
for the avoidance of insomnia (£1083, 95% CI £500-£1664), then one tablet per day 
(£934, CI £461-£1406), avoidance of a heart attack (£589, CI £231-£947) then avoid-
ing mealtime dosing (£516, CI £242-£790). cOnclusiOns: UK HIV patients have 
a strong preference for avoiding treatment related insomnia, followed by a single 
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reservations have restricted market access thus increasing co-pays. This is driven 
by stakeholder concerns on non-compliance leading to drug resistance, promiscuity, 
and development off a false sense of security resulting in a drop in HIV screening 
rates and protective measures. The gravity of the issue is judged by the fact that, 
FDA has called for a REMS to take care of these issues. cOnclusiOns: The utiliza-
tion of a new medical service is impacted by societal perceptions, especially those 
conflicting with general values. In spite of regulatory approvals and national recom-
mendations supported by clinical evidences, low adoption and high co-pays reflects 
that the market access is significantly driven by strong prevailing societal views.
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Objectives: Two human papillomavirus (HPV) vaccines were licensed to prevent 
HPV infections, but the utilization remains low in the United States (US). Previous 
trend studies about HPV vaccine utilization in the US are scarce and their conclusions 
are subject to internal invalidities due to methodological flaws. This study aimed to 
reinvestigate the trend of HPV vaccine utilization including uptake, completion, and 
adherence by using more accurate measurement and sophisticated statistical meth-
ods. MethOds: This was a retrospective cross-sectional study. Subjects aged 11-32 
in the National Health and Nutrition Examination Survey 2011-2012 were extracted. 
Two constructs of the Andersen healthcare utilization model were adapted for vari-
ables selection. Heckman two-step sample selection models along with logistic and 
Poission regressions were performed to examine variables associated with vaccine 
uptake, completion, and adherence. Results: Among study subjects (weighted N= 
92,290,848), 19.7% were HPV vaccine users. Factors positively related to vaccine uptake 
included being female, younger age, going to a doctor’s office or hospital for most 
healthcare services, and having Medicaid or other public insurance. Among HPV vac-
cine users, higher income was positively related to vaccine completion and adher-
ence. Vaccine completion rate did not increase overtime. Nonetheless, subjects who 
received their first dose of HPV vaccine between 2008 to 2010 had better adherence, 
compared with subjects who received their first dose in 2006, the vaccine introduc-
tion year. cOnclusiOns: We observed disparities in HPV vaccine uptake, indicating 
that expanding insurance coverage to HPV vaccine and increasing vaccine access 
through primary care services could be efficient ways to improve the low HPV vaccine 
initiation rate in the US. Additionally, the increasing trend of HPV vaccine utiliza-
tion observed from previous studies could be mistaken due to secular accumulation 
overtime. Because the vaccine completion rate actually did not increase over time, 
more efforts should be addressed to ensure vaccine completion.
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Objectives: Vaccines are one of the greatest triumphs of healthcare innovation. 
They have saved millions of lives, prevented destructive chronic illnesses and eased 
pressures on health services across the globe. However, it is surprisingly difficult 
for manufacturers trying to navigate the UK government system. We provide an 
outline of the route to potential reimbursement, using recent examples, and guid-
ance based on lessons learned. MethOds: Published UK articles, The Health and 
Social Care Act 2012 and government and industry records were scrutinised and 
summarised into an outline of the process to make vaccines available. Examples of 
vaccines, the challenges they have faced and potential solutions to those challenges 
were examined. Results: Once a licence has been obtained, usually through the 
European Medicines Agency, the Joint Committee on Vaccination and Immunisation 
(JCVI), makes recommendations to the Department of Health (DH). The JCVI covers 
all UK countries (subject to potential devolution of powers to Scotland). The JCVI is 
considering allowing industry to attend Committee meetings, which would be a 
huge step forward for such a secretive body. There is no scoping phase, limited stake-
holder engagement; recommendations are not made public and their rationale not 
given, and there is no appeal element to the process. The DH agrees the price of each 
vaccine, which in a recent example took around a year, with input from NHS England 
(NHSE) and Public Health England (PHE). PHE is then responsible for implementation 
and procurement through its Health Protection Directorate. To draw together this 
process, the NHSE and DH jointly convene a Senior Oversight Committee, chaired 
by NHSE. cOnclusiOns: Companies proposing to bring vaccines to market need 
to pay special attention, well in advance, to navigating this complicated structure. 
This is needed to achieve a satisfactory price, which rewards R&D and other costs, 
within a reasonable period.
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Objectives: Incentivizing antibiotic development in advance of resistance devel-
opment is a critical global health policy issue. A number of policy initiatives are 
under development globally. Some focus on alternative reward mechanisms inclu-
sive of lump sum payments; others focus on enhanced reimbursement once the 
drugs reach market. Understanding how the timing and magnitude of the rewards 
impact antibiotic R&D investment decisions is essential to effective and efficient 
policy development. MethOds: The R&D portfolio investment decision process and 
anticipated cash flow for antibiotics is modeled using decision trees composed of 
deterministic decision nodes and probabilistic uncertainties. (e.g., the probability 
of success during phase 2 trials). Monte Carlo simulations and calculations for net 
present values and the decision options at the various nodes are incorporated into 
the decision tree analysis in order to provide insights into the valuations at the vari-
availability of novel 2GDAAs. Treatment patterns are sensitive to market entry of 
new HCV medications. HCV treatment selection and duration may be influenced 
by disease severity and treatment history.
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Objectives: Cachexia is characterized by a loss in muscle mass leading to an overall 
reduction in function and is often related to severe chronic conditions such as can-
cer, kidney disease and HIV. Anabolic steroids (AS) have been seen as a potential aid 
to reducing the impact of cachexia in HIV patients, but AS therapy remains contro-
versial. The purpose of this study was to characterize HIV related cachexia patients 
and look for differences between those treated or not treated with AS. MethOds: 
To complete this study we used Medicare LDS 5% random sample for 2011-2013. 
Patients were identified as having HIV (ICD-9 code 042) and then cachexia (ICD-9 
code 799.4, 783.0, 783.2, and 783.3) using inpatient and outpatient claims. AS treat-
ment was identified using HCPCS J codes. Among those with cachexia, patients 
receiving AS were compared to those who were not using frequencies, means, t-test, 
and chi-square statistics. Results: There were over 4,000 HIV patients in the sam-
ple, 1,835 of which had cachexia. Only 54 patients received AS therapy, but there 
were still differences between treated and non-treated patients in terms of gender 
(90.74% and 72.09%, respectively, p= 0.01) and race (66.67% and 45.65%, respectively, 
p= 0.03). Treated patients had higher CCI scores (11.72 versus 9.75, p= 0.01). In each 
group 75% of individuals received Medicare benefits because of chronic disability. 
Treated and untreated patients had similar ER and inpatient visits as well as simi-
lar total costs ($43,085.76 versus $29,930.82, inpatient, p= 0.07). cOnclusiOns: In 
this study we have seen that in HIV related cachexia those patients who receive AS 
therapy for cachexia are the most severe of an already severely ill group. This study 
indicates that AS treatment is being used as a last resort instead of earlier in the 
cachexic process when the treatment could potentially have a larger impact on a 
patient’s disease progression.
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Objectives: Over 100,000 people in the UK are living with human immuno-
deficiency virus (HIV). This once acute condition has been transformed into a 
near chronic condition by antiretroviral treatment (ART), providing people living 
with HIV (PLHIV) remain virologically suppressed. In order to maintain suppres-
sion, patients must adhere to ART. Single tablet ART regimens (STRs) are a recent 
advance aimed at improving adherence. However, PLHIV are more likely to develop 
non-AIDS related morbidities (NARMs) including diabetes and chronic kidney 
disease than the general population. Our objective was to develop a HIV model 
with the ability to capture adherence and NARMs, suitable for health technology 
assessments. MethOds: A review of HIV models concluded that existing models 
do not adequately account for either adherence benefits associated with STRs or 
the impact of non-AIDS related morbidities. We developed an individual patient 
simulation model in R to predict clinical and economic outcomes of ART in treat-
ment naïve patients. Patients move through a clinically validated treatment path-
way based on previous treatments and standard of care. The probability of viral 
suppression at 48 weeks for each antiretroviral treatment, informed by a recent 
network meta-analysis, determines whether CD4 levels will increase or decrease. 
The level of CD4, along with patient’s characteristics and current antiretroviral 
treatment, are used to predict NARMs, opportunistic infections and morbidities. 
Adherence to treatment modifies the long term probability of remaining virologi-
cally suppressed. Results: Our model predicts overall survival, CD4 over time 
and event rates that concur with long term studies in HIV. The model also predicts 
other clinical and economic outcomes including time on first treatment, QALYs 
and cost, stratified by resource category. cOnclusiOns: This model is the first, 
to our knowledge, to incorporate the adherence benefit of STRs and the impact of 
NARMs on estimates of cost-effectiveness of ART in HIV.
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Objectives: Studies in literature have shown that the rates of awareness, intent 
and use of HPV vaccines and HIV preventive therapies rose during first years of 
launch but have dropped subsequently. The objective of this study is to assess the 
impact of social and behavioral factors on the acceptance and usage of these thera-
pies. MethOds: A detailed review of medical literature, journals, regulatory publi-
cations, and physician blogs on HPV and HIV preventive therapies was conducted. 
Our research has been structured by exemplifying two case studies assessing the 
impact of stakeholders’ opinions on acceptance and adoption of vaccines and pre-
ventive therapies Results: case study 1 Although EMEA approved HPV vaccines 
in 2006, their coverage remains suboptimal. These vaccines continue to have low 
adoption throughout Europe, compared to other adult vaccines. This is attribut-
able to apprehensive views among stakeholders, such as parents, having concerns 
on promiscuity and vaccine safety. Similar views were observed among European 
press and religious groups. The attitude of physicians also had a nebulous outlook, 
impacting adoption. case study 2 A similar scenario exists in the US, with PrEP 
HIV preventive therapy. Although medical literature supports the therapy, societal 
